Dia-Clarus s.r.o.
- Address
- Janka Krala 573/15, 972 01 Bojnice, Slovakia
Dia-Clarus s.r.o. - Diabetes Research Center
Dia-Clarus s.r.o. is a specialized clinical research facility dedicated to advancing diabetes care through innovative therapeutic approaches. The center focuses on optimizing treatment strategies for patients with type 2 diabetes, particularly those managing overweight and insulin therapy.
- Type 2 diabetes mellitus treatment optimization studies
- Comparative efficacy trials of semaglutide and insulin combinations
- Glycemic control assessment using HbA1c endpoints
The research center demonstrates expertise in basal insulin optimization and novel GLP-1 receptor agonist therapies, conducting non-inferiority trials that evaluate dose-reduction strategies. Their work contributes to understanding how combination therapies with semaglutide and insulin glargine can improve outcomes while potentially reducing insulin requirements in patients with type 2 diabetes and overweight, addressing both metabolic control and treatment burden.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novo Nordisk A/S1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dia-Clarus s.r.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Semaglutide with Reduced-Dose Insulin Glargine Versus Titrated Insulin Glargine in Type 2 Diabetes with Overweight | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2022 | Apr 2025 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 2 | Unknown | 2022-08-31 | 2026-07-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.